Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resista...
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
About this item
Full title
Author / Creator
Li, Qing-Hai , Wang, Ying-Zhao , Tu, Jian , Liu, Chu-Wei , Yuan, Yu-Jie , Lin, Run , He, Wei-Ling , Cai, Shi-Rong , He, Yu-Long and Ye, Jin-Ning
Publisher
Oxford: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer (mCRC). These agents have good curative efficacy, but drug resistance also exists at the same time. The effects of KRAS, NRAS, and BRAF mutations and HER2 amplifica...
Alternative Titles
Full title
Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7333932
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7333932
Other Identifiers
ISSN
2052-0034
E-ISSN
2052-0034
DOI
10.1093/gastro/goaa026
